Healthcare ❯ Pharmaceuticals

Cancer Treatment

Keytruda Drug Approval Clinical Trials Gastrointestinal Stromal Tumors FDA Approval Drug Management Darzalex Medication Supply Rare Tumors Rare Tumours Billing Fraud Chemotherapy Cytostatics Oncology Bladder Cancer ISB 2001 Bladder Cancer Drugs Bispecific Antibodies Lung Cancer Advanced Therapies Monoclonal Antibodies Zytostatika Opdivo Innovative Therapies Personalized Cancer Treatment Drug Development Innovation Radioconjugates

Merck Ends Revolution Medicines Takeover Talks After Valuation Standoff

Interest centered on Revolution’s late-stage pan‑RAS drug daraxonrasib, a key driver of the biotech’s standalone prospects.

Merck Lifts Mid-2030s Revenue Goal to $70 Billion From Emerging Businesses

Bristol Myers Enters 2026 With Eliquis Medicaid Pact, Opdivo Qvantig Rollout, and Divergent Analyst Views

Crescent, Kelun-Biotech Trade Cancer Asset Rights in Cross-Border Deal as Crescent Secures $185 Million